Earlier this month, we reported on how Susanne Stoll, a graduate student in the Department of Experimental Psychology at the University College London, discovered an error that toppled a highly-cited 2014 article — and which might affect hundreds of other papers in the field of perception.
We spoke with Stoll about the experience.
Retraction Watch (RW): What did it feel like to find such a significant error? Did you doubt yourself at first, and, if so when did you realize you’d found something both real and important?
Bowing to legal pressure from the supplement maker Herbalife, Elsevier earlier this year retracted — and then removed — a paper which claimed that a young woman in India died of liver failure after using the company’s products. The move has led to more legal threats.
The group, led by Cyriac Abby Philips, of Cochin Gastroenterology, in Kerala, India, asserted that tests of Herbalife products similar to those the woman had been taking revealed the presence of heavy metals, bacteria and, in most samples, “undisclosed toxic compounds including traces of psychotropic recreational agent.”
A pharmacologist at the University of Texas Southwestern Medical Center who lost a highly cited 2014 paper in Nature for questions about the integrity of her data has been sanctioned by the U.S. Office of Research Integrity (ORI) — and UT Southwestern has rescinded two professorships she previously held.
A sports medicine journal has retracted a widely circulated 2019 meta-analysis which purported to find that interval training was the “magic bullet” for weight loss, after the analysis proved to be riddled with holes.
Steele has some cred when it comes to research integrity, and part of that cred comes from another retraction. He was part of a team of data sleuths who have called for the retraction of seven papers by Matheus Barbalho, a Brazilian exercise scientist.
More than six months after two of the world’s leading medical journals retracted papers on COVID-19 based on suspect data from a questionable company, a journal says it has cleared a raft of articles by the controversial founder of the firm. Or, has it?
Vascular, a SAGE title, says it has investigated all papers in the journal by Sapan Desai that relied on “a significant amount of data,” whatever that means. Desai, you’ll recall, founded Surgisphere, which is now famous for refusing to share its data in articles published in The Lancet and The New England Journal of Medicine.
We counted 18 11 papers in Vascular on which Desai was a co-author. The journal says — in a rather oblique way — that all but two of the articles it examined either checked out or didn’t include enough data to raise alarms.
A team of researchers in England has retracted a 2014 paper after a graduate student affiliated with the group found a fatal error while trying to replicate parts of the work — and which might affect similar studies by other scientists, as well.
The article, “Perceptual load affects spatial tuning of neuronal populations in human early visual cortex,” was written by Benjamin de Haas, then of the Institute of Cognitive Neuroscience at the University College London, and his colleagues at UCL.
An associate dean at the University of Miami stepped down from his post two weeks after agreeing to sanctions stemming from a finding of misconduct by a government watchdog, Retraction Watch has learned.
Yesterday, we reported that the U.S. Office of Research Integrity (ORI) found that Charles Downs, “engaged in research misconduct by intentionally, knowingly, or recklessly falsifying and/or fabricating data” in six federal grant applications while on the faculty of the University of Arizona.
Downs was appointed associate dean of Miami’s nursing school in 2018, and stepped down from the position on December 4, according to a university spokesperson. He remains an associate professor at the school.
A former researcher at the University of Arizona who is now was until last week an associate dean at the University of Miami “engaged in research misconduct by intentionally, knowingly, or recklessly falsifying and/or fabricating data” in six federal grant applications, according to a new finding by the U.S. Office of Research Integrity (ORI).
Charles A. Downs’ work “focuses on acute lung injury and pulmonary diseases,” according to a 2018 press release from the University of Miami announcing his appointment. He “neither admits nor denies ORI’s findings of research misconduct,” the ORI announced today. The agency said that Downs
A pharmacy researcher at Tehran University of Medical Sciences has had three papers retracted, and one corrected, because he duplicated his other articles.
Narges Shokri, of the School of Pharmacy of Ardabil University of Medical Sciences, also in Iran, is an author of the three retracted papers, but not the corrected paper in the International Journal of Molecular Medicine.
Here’s the notice for “Comparison of Calcium Phosphate and Zinc Oxide Nanoparticles as Dermal Penetration Enhancers for Albumin,” in the Indian Journal of Pharmaceutical Sciences:
An investigation into the work of a researcher at Western University “resulted in a clear determination of research misconduct,” according to a retraction notice, but details are scant.
